U.S. Army Validates SteraMist iHP Technology’s Efficacy on Various Biological Toxoids, Including Ricin
Study Shows SteraMist iHP Outperforms Vaporized Hydrogen Peroxide in Speed and Material Integrity
FREDERICK, Md., May 31, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced the completion of a study conducted in accordance with the U.S. Department of Defense (DoD) Biological Select Agents and Toxins (BSAT) Biorisk Program Office (BBPO) which demonstrated SteraMist iHP as an effective technology for decontamination of biological toxoids.
The study aimed to determine if biological toxins can be decontaminated by iHP at a shorter exposure time as compared to Vaporized Hydrogen Peroxide (VHP). VHP, while a powerful decontamination tool, is time consuming, sensitive to temperature and humidity, can cause material compatibility concerns after repeated exposures, and contains an H2O2 starting solution that’s both hazardous and difficult to transport.
The study utilized a SteraMist Select Surface Unit, a fully portable, robust, decontamination unit, capable of biological remediation via both direct spray application and small space automated fogging, along with TOMI’s Binary Ionization Technology (BIT) solution. The two material types tested were stainless steel and polycarbonate Lexan, while the toxoids investigated were:
- Ricin A chain toxoid, a potent cell toxin designated as a Category B bioterrorism agent and a Schedule number 1 chemical warfare agent by the DoD
- Staphylococcus enterotoxin B toxoid (SEB), a potent bacterial superantigen and Category B bioterrorism agent
- Clostridium botulinum type A toxin complex toxoid (Bot), a foodborne pathogenic bacteria and Category A bioterrorism agent
The findings confirmed the efficacy of iHP as an effective method for decontaminating biological toxoids in accordance with BBPO guidelines and indicated that iHP may offer a quicker decontamination process for ricin compared to VHP sterilization. Furthermore, no signs of material deterioration or degradation were observed. The complete findings can be downloaded here.
"These results validate the significant potential of iHP as a powerful technology for decontaminating biological toxoids,” states Elissa J. (E.J.) Shane, COO of TOMI. “The study demonstrated effectiveness, rapidity, and absence of material degradation. We believe this will open new avenues for enhancing biosecurity and protecting against biological threats, fueling optimism for a safer and more secure future. We look forward to the continuation of our partnership with the U.S. Department of Defense. "
TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology ® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide (iHP™) technology in all SteraMist systems to create superior disinfection. TOMI products are designed to service a broad spectrum of use sites, including, but not limited to, hospitals and medical facilities, biosafety labs, pharmaceutical facilities, commercial and office buildings, schools, restaurants, meat and produce processing facilities, and police and fire departments.
For additional information, please visit https://steramist.com/ or contact us at info@tomimist.com
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to the potential of iHP technology and SteraMist’s opportunities in new partnerships. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Forward-looking statements involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control. As such, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors. Important factors that could affect our performance and cause results to differ materially from management’s expectations are described in the section entitled “Risk Factors,” in our Annual Report on Form 10-K and other SEC filings. These factors include: our history of losses that may prevent us from achieving profitability in the future; our lack of long-term customer contracts and our inability to rely on our sales history or backlog as an indicator of our future sales; that we are subject to a variety or risks associated with doing business internationally; our success in business depends on our ability to adequately protect our intellectual property; and that our stock price is volatile and there is a limited market for our shares. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:
John Nesbett/Rosalyn Christian
IMS Investor Relations
tomi@imsinvestorrelations.com
